Key Highlights
- The U.S. Patent and Trademark Office has issued U.S. Patent No. 12,797,335 covering a buspirone tablet formulation using Cingulate's proprietary PTR technology.
- The patented formulation is designed to release medication at three separate, predetermined times throughout the day from a single tablet.
- The patent supports development of CTx-2103 for anxiety disorders and demonstrates the broader applicability of the PTR platform beyond ADHD.
- Cingulate remains focused on advancing its lead ADHD candidate CTx-1301 toward NDA resubmission in the second half of 2027.
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company focused on its proprietary Precision Timed Release (PTR) drug delivery platform, has announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,797,335. The patent, titled "Trimodal, Precision-Timed Release Tablet," covers a buspirone tablet formulation incorporating the company's PTR technology. Buspirone is an FDA-approved treatment for anxiety disorders.
The patent was issued on November 17, 2026, and covers a pharmaceutical tablet formulation designed to deliver three separate releases of an active pharmaceutical ingredient at predetermined intervals following administration from a single oral dosage form.
How Does This Expand Cingulate's IP Portfolio?
The newly issued patent supports Cingulate's development of CTx-2103, an investigational candidate for anxiety disorders. The company has stated that the patent further demonstrates the versatility and broader applicability of its PTR technology beyond its initial focus on ADHD.
Cingulate's lead candidate, CTx-1301 (dexmethylphenidate HCl), is being developed for the treatment of ADHD. The FDA issued a Complete Response Letter for the CTx-1301 NDA on June 1, 2026. The company has since substantially completed the Manufacturing work required to address the Chemistry, Manufacturing, and Controls (CMC) requests and expects to resubmit the NDA between December 2026 and January 2027.
Chairman and CEO Shane J. Schaffer stated that following approval of CTx-1301, Cingulate anticipates initiating the development of CTx-2103, calling it an attractive opportunity to build a pipeline of Assets beyond ADHD.
What Is the PTR Technology Platform?
Cingulate's PTR platform is designed to achieve true once-daily dosing through a multi-core tablet formulation. The technology incorporates a proprietary Erosion Barrier Layer (EBL) that controls drug release at precise, pre-defined times with no release of drug prior to the intended time. The EBL technology is enrobed around a drug-containing core in a tablet-in-tablet dose form.
The EBL formulation, called Oralogik, is licensed from BDD Pharma. Cingulate intends to utilize the PTR technology to expand its clinical-stage pipeline by identifying and developing additional product candidates in therapeutic areas beyond ADHD and anxiety.
What Is the Market Context for Anxiety Treatments?
Anxiety disorders are the most common category of mental disorders in the United States, affecting nearly 30% of adults at some point during their lives, according to the American Psychiatric Association. The National Institute of Mental Health estimates that 31.1% of U.S. adults experience an anxiety disorder at some point. Despite the availability of effective treatments, anxiety disorders frequently go undiagnosed or untreated, with delays between symptom onset and initial treatment extending for many years.
CTx-2103 is designed as a once-daily, modified-release tablet that would differentiate itself from standard buspirone treatments, which must be taken multiple times per day. Cingulate has completed a proof-of-concept study confirming the pharmacokinetic profile and triple release of buspirone from the CTx-2103 formulation.
The Path Forward for Cingulate
Cingulate's near-term focus remains on advancing CTx-1301 toward NDA resubmission and potential commercialization. The CTx-2103 program is positioned as a follow-on opportunity that would expand the company's pipeline into the anxiety disorder market, leveraging the same PTR platform technology.


_11_20_2026_20_27_34_097200.jpg)



Please wait processing your request...